Cargando…

Long-Term Radiographic and Patient-Reported Outcomes in Patients with Rheumatoid Arthritis Treated with Tofacitinib: ORAL Start and ORAL Scan Post-hoc Analyses

INTRODUCTION: Here we examine the relationship between achieving different levels of disease activity with tofacitinib (an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis), long-term structural progression, and patient-reported physical function. METHODS: This was a post hoc an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Strand, Vibeke, Kavanaugh, Arthur, Kivitz, Alan J., van der Heijde, Désirée, Kwok, Kenneth, Akylbekova, Ermeg, Soonasra, Arif, Snyder, Mark, Connell, Carol, Bananis, Eustratios, Smolen, Josef S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2018
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251846/ https://www.ncbi.nlm.nih.gov/pubmed/29761420 http://dx.doi.org/10.1007/s40744-018-0113-7

Ejemplares similares

Relationship between clinical and patient-reported outcomes in a phase 3 trial of tofacitinib or MTX in MTX-naïve patients with rheumatoid arthritis
por: Fleischmann, Roy, et al.
Publicado: (2016)

Evaluation of disease activity in patients with rheumatoid arthritis treated with tofacitinib by RAPID3: post hoc analyses from two phase 3 trials
por: Strand, Vibeke, et al.
Publicado: (2018)

Joint-level responses to tofacitinib and methotrexate: a post hoc analysis of data from ORAL Start
por: Ciurea, Adrian, et al.
Publicado: (2023)

Tofacitinib, an oral Janus kinase inhibitor, in patients from Brazil with rheumatoid arthritis: Pooled efficacy and safety analyses
por: Lomonte, Andrea B.V., et al.
Publicado: (2018)

Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial
por: Strand, Vibeke, et al.
Publicado: (2016)

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty‐Four–Month, Phase III Study
por: van der Heijde, Désirée, et al.
Publicado: (2019)

Differences and similarities in clinical and functional responses among patients receiving tofacitinib monotherapy, tofacitinib plus methotrexate, and adalimumab plus methotrexate: a post hoc analysis of data from ORAL Strategy
por: Takeuchi, Tsutomu, et al.
Publicado: (2021)

Is radiographic progression in modern rheumatoid arthritis trials still a robust outcome? Experience from tofacitinib clinical trials
por: Landewé, Robert B. M., et al.
Publicado: (2016)

DAS28-CRP and DAS28-ESR cut-offs for high disease activity in rheumatoid arthritis are not interchangeable
por: Fleischmann, Roy M, et al.
Publicado: (2017)

Assessment of radiographic progression in patients with rheumatoid arthritis treated with tofacitinib in long-term studies
por: van der Heijde, Désirée, et al.
Publicado: (2020)

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
por: Charles-Schoeman, Christina, et al.
Publicado: (2016)

Herpes Zoster and Tofacitinib: Clinical Outcomes and the Risk of Concomitant Therapy
por: Winthrop, Kevin L., et al.
Publicado: (2017)

An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective
por: Claxton, Lindsay, et al.
Publicado: (2018)

Efficacy of tofacitinib in patients with rheumatoid arthritis stratified by background methotrexate dose group
por: Fleischmann, R, et al.
Publicado: (2016)

Rheumatoid arthritis disease activity and adverse events in patients receiving tofacitinib or tumor necrosis factor inhibitors: a post hoc analysis of ORAL Surveillance
por: Karpouzas, George A., et al.
Publicado: (2023)

Efficacy and safety of tofacitinib by background methotrexate dose in psoriatic arthritis: post hoc exploratory analysis from two phase III trials
por: Kivitz, Alan J., et al.
Publicado: (2021)

Certolizumab pegol plus methotrexate 5-year results from the rheumatoid arthritis prevention of structural damage (RAPID) 2 randomized controlled trial and long-term extension in rheumatoid arthritis patients
por: Smolen, Josef S., et al.
Publicado: (2015)

Oral tofacitinib citrate for recalcitrant cutaneous lupus
por: Bonnardeaux, Evelyne, et al.
Publicado: (2021)

Associations between Patient Global Assessment scores and pain, physical function, and fatigue in rheumatoid arthritis: a post hoc analysis of data from phase 3 trials of tofacitinib
por: Strand, Vibeke, et al.
Publicado: (2020)

Tofacitinib Prevents Radiographic Progression in Rheumatoid Arthritis
por: Kim, Joon Wan, et al.
Publicado: (2013)

Oral Tofacitinib: Contemporary Appraisal of Its Role in Dermatology
por: Sonthalia, Sidharth, et al.
Publicado: (2019)

Sisaipho alopecia areata treated with tofacitinib and oral minoxidil
por: Talty, Ronan, et al.
Publicado: (2022)

Oral Tofacitinib Therapy for the Effective Management of Netherton Syndrome
por: Dodeja, Ajay, et al.
Publicado: (2023)

Response to Oral Tofacitinib in Childhood Refractory Nipple Eczema
por: Asritha, C V V, et al.
Publicado: (2023)

Patient-reported outcomes for tofacitinib with and without methotrexate, or adalimumab with methotrexate, in rheumatoid arthritis: a phase IIIB/IV trial
por: Strand, Vibeke, et al.
Publicado: (2019)

Sex differences in the efficacy, safety and persistence of patients with psoriatic arthritis treated with tofacitinib: a post-hoc analysis of phase 3 trials and long-term extension
por: Eder, Lihi, et al.
Publicado: (2023)

Precautions before starting tofacitinib in persons with rheumatoid arthritis
por: Swarnakar, Raktim, et al.
Publicado: (2022)

Alport Syndrome and Oral Mucous Membrane Pemphigoid: An Interesting Case
por: Zisis, Vasileios, et al.
Publicado: (2023)

Structural damage in rheumatoid arthritis as visualized through radiographs
por: van der Heijde, Désirée
Publicado: (2002)

Oral Janus Kinase Inhibitor for the Treatment of Rheumatoid Arthritis: Tofacitinib
por: Ni, Han, et al.
Publicado: (2013)

Amelioration of unstable vitiligo and normalization of thryroglobulin antibodies with oral tofacitinib
por: Moore, Angela Yen, et al.
Publicado: (2022)

Clinical response to oral tofacitinib in pediatric patients with alopecia areata
por: Youssef, Soundos, et al.
Publicado: (2022)

Two cases of bullous pemphigoid effectively treated with oral tofacitinib
por: Youssef, Soundos, et al.
Publicado: (2022)

A retrospective study of oral tofacitinib therapy for alopecia areata()
por: Lima, Xinaida Taligare Vasconcelos, et al.
Publicado: (2023)

Tofacitinib for the Treatment of Ulcerative Colitis: Analysis of Nonmelanoma Skin Cancer Rates From the Ulcerative Colitis Clinical Program
por: Sands, Bruce E, et al.
Publicado: (2021)

Effects of tofacitinib monotherapy on patient-reported outcomes in a randomized phase 3 study of patients with active rheumatoid arthritis and inadequate responses to DMARDs
por: Strand, Vibeke, et al.
Publicado: (2015)

Efficacy and safety of palbociclib in patients with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer with preexisting conditions: A post hoc analysis of PALOMA-2
por: Gelmon, Karen, et al.
Publicado: (2021)

Clinical utility of the oral JAK inhibitor tofacitinib in the treatment of rheumatoid arthritis
por: Cutolo, Maurizio, et al.
Publicado: (2013)

Refractory Takayasu arteritis responding to the oral Janus kinase inhibitor, tofacitinib
por: Yamamura, Yuriko, et al.
Publicado: (2019)

Tailoring Tofacitinib Oral Therapy in Rheumatoid Arthritis: The TuTOR App
por: Radin, Massimo, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_bvmc92kode4av1dnfli1ttco3n